Ventyx Biosciences GAAP EPS of -$0.32

* Ventyx Biosciences press release [https://seekingalpha.com/pr/20297770-ventyx-biosciences-reports-third-quarter-2025-financial-results-and-highlights-recent] (VTYX [https://seekingalpha.com/symbol/VTYX]): Q3 GAAP EPS of -$0.32.
* Cash, cash equivalents and marketable securities balance of $192.6M as of September 30, 2025, expected to fund planned operations into at least H2 2026

MORE ON VENTYX BIOSCIENCES

* Ventyx Biosciences, Inc. (VTYX) Discusses Positive Phase II Results of VTX3232 in Obesity and Cardiovascular Risk Factors Transcript [https://seekingalpha.com/article/4832829-ventyx-biosciences-inc-vtyx-discusses-positive-phase-ii-results-of-vtx3232-in-obesity-and]
* Ventyx Biosciences, Inc. (VTYX) Discusses Positive Phase II Results of VTX3232 in Obesity and Cardiovascular Risk Factors - Slideshow [https://seekingalpha.com/article/4832833-ventyx-biosciences-inc-vtyx-discusses-positive-phase-ii-results-of-vtx3232-in-obesity-and]
* Ventyx Biosciences: At Last, A Data Win In CV - But Clarity On Next Steps Needed [https://seekingalpha.com/article/4832602-ventyx-biosciences-at-last-a-data-win-in-cv-but-clarity-on-next-steps-needed]
* Ventyx surges on mid-stage trial data for heart disease drug [https://seekingalpha.com/news/4507405-ventyx-up-mid-stage-trial-data-heart-drug]
* Seeking Alpha’s Quant Rating on Ventyx Biosciences [https://seekingalpha.com/symbol/VTYX/ratings/quant-ratings]